Onychomycosis Treatment Market Report 2026

Onychomycosis Treatment Market Overview

• Onychomycosis Treatment market size has reached to $3.91 billion in 2025 • Expected to grow to $5.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Surge In Fungal Infections Fueling Growth In The Onychomycosis Treatment Market • Market Trend: Increasing Focus On Innovative Product Approval To Gain A Competitive Edge • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Onychomycosis Treatment Market?

Onychomycosis treatment refers to the medical interventions and approaches used to manage and cure onychomycosis, a fungal infection that affects the nails, including both the fingernails and toenails. Treating onychomycosis typically involves a combination of topical and oral antifungal medications and preventive measures to reduce the risk of recurrence. The main types of onychomycosis are distal sublingual onychomycosis, white superficial onychomycosis, proximal sublingual onychomycosis, candida onychomycosis and others. Distal sublingual onychomycosis is a fungal nail infection affecting the undersurface of the nail tip, typically caused by dermatophyte fungi. Various types of treatments include drugs, laser therapy and photodynamic therapy, which are used to treat various age groups, including 0 to 18 years, 18 to 39 years, 40 to 64 years and 65 years and above. Several distribution channels are included, such as hospital pharmacies, retail pharmacies and others.

What Is The Onychomycosis Treatment Market Growth Forecast?

The onychomycosis treatment market size is expected to see strong growth in the next few years. It will grow to $5.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to advancement in laser and photodynamic therapy technologies, increasing adoption of combination treatment approaches, rising telemedicine consultations for dermatology, expansion of hospital and retail pharmacy distribution, growing research and development for drug-resistant fungal strains. Major trends in the forecast period include increasing adoption of combination drug and laser therapies, rising use of photodynamic therapy for recalcitrant infections, growing awareness about preventive nail care, increasing implementation of ai-based diagnostic tools for fungal infections, rising telemedicine adoption for onychomycosis treatment.

Global Onychomycosis Treatment Market Segmentation

1) By Type: Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candida Onychomycosis, Other Types 2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy 3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

What Is The Driver Of The Onychomycosis Treatment Market?

The increasing number of fungal infections is expected to propel the growth of the onychomycosis treatment market going forward. Fungal infections are microbial diseases caused by various fungi, affecting different body parts or causing specific conditions. Onychomycosis (a fungal nail infection) is typically treated with oral antifungal medications or topical antifungal solutions to eliminate the underlying fungal growth and restore healthy nail growth. For instance, in May 2025, according to the UK Health Security Agency, a UK-based government agency, in 2024, the rate of bloodstream infections due to yeasts across England had increased by 31% since 2015 and by 4% from 2023. Further, between 2023 and 2024 there was a 4% increase in the number of laboratory reports of fungemia due to yeasts (from 2,170 to 2,247 reports) in England. Therefore, the increasing number of fungal infections is driving the growth of the onychomycosis treatment industry.

Key Players In The Global Onychomycosis Treatment Market

Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd.

Global Onychomycosis Treatment Market Trends and Insights

Major companies operating in the onychomycosis treatment market are focused on developing new products, such as MOB-015, and getting them approved by federal agencies to gain a competitive edge in the market. For instance, in June 2023, Moberg Pharma AB, a Sweden-based pharmaceutical company, received approval for MOB-015 in the European Union for treating mild to moderate fungal infections of the nails in adults. The European Union's approval marks the innovative onychomycosis medication's first global marketing authorization. Two Phase 3 trials supporting MOB-015's approval demonstrated improved mycological cure (76% vs. up to 42% for comparators) and a much greater total cure rate than the vehicle, all without experiencing any serious adverse effects. The topical terbinafine formulation MOB-015 allows effective terbinafine concentrations to reach the nail and nail bed without the risk of systemic exposure associated with oral terbinafine treatment.

What Are Latest Mergers And Acquisitions In The Onychomycosis Treatment Market?

In August 2023, Karo Healthcare AB, a Sweden-based consumer healthcare company, acquired Lamisil from Haleon PLC for approximately $297.86 million. The acquisition of Lamisil enhances Karo Healthcare's OTC (over-the-counter) offering and expands its foot health portfolio. This transaction increases Karo's geographical presence and market share in foot health. Lamisil is an oral antifungal drug that is commonly used for the treatment of onychomycosis. Haleon PLC is a UK-based consumer healthcare company providing onychomycosis treatment.

Regional Outlook

North America was the largest region in the onychomycosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Onychomycosis Treatment Market?

The onychomycosis treatment market consists of revenues earned by entities by providing combination therapy, nail debridement and Carbon dioxide ablative laser treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The onychomycosis treatment market also includes sales of griseofulvin, terbinafine, itraconazole, ketoconazole and more. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Onychomycosis Treatment Market Report 2026?

The onychomycosis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the onychomycosis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.